目次

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY
1.1 MARKET SYNOPSIS

2 MARKET INTRODUCTION
2.1 SCOPE OF THE STUDY
2.2 RESEARCH OBJECTIVE
2.3 LIST OF ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.3.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
3.3.2 BREAKDOWN OF PRIMARY RESPONDENTS
3.4 FORECASTING TECHNIQUES
3.5 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.5.1 BOTTOM-UP APPROACH
3.5.2 TOP-DOWN APPROACH
3.6 DATA TRIANGULATION
3.7 VALIDATION

4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 RISING R&D IN THE PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES
4.2.2 INCREASING APPLICATION OF CELL LINES IN BIOTECH & PHARMACEUTICAL COMPANIES AND HOSPITALS
4.2.3 RISING PREVALENCE OF CANCER AND OTHER CHRONIC DISEASES
4.3 RESTRAINTS
4.3.1 HIGH MAINTENANCE COSTS AND DEARTH OF SKILLED STAFF
4.3.2 COMPLEXITY INVOLVED IN DEVELOPING STABLE AND AUTHENTIC CELL LINES
4.4 OPPORTUNITY
4.4.1 RISING ADOPTION OF MAMMALIAN SOURCES FOR ANTIBODY PRODUCTION
4.4.2 TECHNOLOGICAL INNOVATION IN CELL LINE DEVELOPMENT

5 MARKET FACTOR ANALYSIS
5.1 SUPPLY CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 SALES & MARKETING
5.1.4 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE GLOBAL CELL LINE DEVELOPMENT MARKET
5.3.1 OVERVIEW
5.3.2 IMPACT ON DEMAND
5.3.3 IMPACT ON SUPPLY
5.3.4 IMPACT ON TRADE (IMPORT/EXPORT)
5.3.5 IMPACT ON KEY PLAYERS

6 GLOBAL CELL LINE DEVELOPMENT MARKET, BY PRODUCT
6.1 OVERVIEW
6.2 EQUIPMENT
6.3 REAGENTS & MEDIA

7 GLOBAL CELL LINE DEVELOPMENT MARKET, BY SOURCE
7.1 OVERVIEW
7.2 MAMMALIAN
7.3 NON-MAMMALIAN
7.3.1 AMPHIBIANS
7.3.2 INSECTS

8 GLOBAL CELL LINE DEVELOPMENT MARKET, BY TYPE
8.1 OVERVIEW
8.2 RECOMBINANT CELL LINES
8.3 HYBRIDOMAS
8.4 CONTINUOUS CELL LINES
8.5 PRIMARY CELL LINES

9 GLOBAL CELL LINE DEVELOPMENT MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 BIOPRODUCTION
9.2.1 MARKET TRENDS AND COMPARATIVE GROWTH RATE OF BISPECIFICS/MULTISPECIFICS AND CELL LINE DEVELOPMENT MARKET
9.2.2 ANTIBODY PRODUCTION
9.2.2.1 MONO
9.2.2.2 BI/MULTI
9.2.3 ENZYME PRODUCTION
9.2.4 HORMONE PRODUCTION
9.2.5 OTHERS
9.3 DRUG DISCOVERY
9.4 TISSUE ENGINEERING
9.5 OTHERS

10 GLOBAL CELL LINE DEVELOPMENT MARKET, BY REGION
10.1 OVERVIEW
10.2 NORTH AMERICA
10.2.1 US
10.2.2 CANADA
10.3 EUROPE
10.3.1 GERMANY
10.3.2 UK
10.3.3 FRANCE
10.3.4 ITALY
10.3.5 SPAIN
10.3.6 SWITZERLAND
10.3.7 REST OF EUROPE
10.4 ASIA-PACIFIC
10.4.1 CHINA
10.4.2 JAPAN
10.4.3 INDIA
10.4.4 SOUTH KOREA
10.4.5 AUSTRALIA
10.4.6 REST OF ASIA PACIFIC
10.5 REST OF THE WORLD
10.5.1 MIDDLE EAST
10.5.2 AFRICA
10.5.3 LATIN AMERICA

11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 GLOBAL CELL LINE DEVELOPMENT MARKET: COMPANY SHARE ANALYSIS
11.3 COMPETITIVE BENCHMARKING
11.4 MAJOR GROWTH STRATEGY IN THE GLOBAL CELL LINE DEVELOPMENT MARKET
11.5 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL CELL LINE DEVELOPMENT MARKET
11.6 KEY DEVELOPMENT ANALYSIS
11.7 KEY DEVELOPMENTS & GROWTH STRATEGIES
11.7.1 PRODUCT LAUNCH/ PRODUCT APPROVAL
11.7.2 MERGER/ACQUISITION
11.7.3 PARTNERSHIP/ AGREEMENT
11.7.4 EXPANSION/ INVESTMENT
11.8 FINANCIAL MATRIX
11.8.1 SALES (USD MILLION), 2020
11.8.2 R&D EXPENDITURE (USD MILLION), 2020

12 COMPANY PROFILES
12.1 LONZA GROUP
12.1.1 COMPANY OVERVIEWS
12.1.2 FINANCIAL OVERVIEW
12.1.3 PRODUCTS/SERVICES OFFERED
12.1.4 KEY DEVELOPMENTS
12.1.5 SWOT ANALYSIS
12.1.6 KEY STRATEGIES
12.2 SELEXIS SA
12.2.1 COMPANY OVERVIEW
12.2.2 FINANCIAL OVERVIEW
12.2.3 PRODUCTS/SERVICES OFFERED
12.2.4 KEY DEVELOPMENTS
12.2.5 SWOT ANALYSIS
12.2.6 KEY STRATEGIES
12.3 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
12.3.1 COMPANY OVERVIEW
12.3.2 FINANCIAL OVERVIEW
12.3.3 PRODUCTS OFFERED
12.3.4 KEY DEVELOPMENTS
12.3.5 SWOT ANALYSIS
12.3.6 KEY STRATEGIES
12.4 THERMO FISHER SCIENTIFIC INC.
12.4.1 COMPANY OVERVIEW
12.4.2 FINANCIAL OVERVIEW
12.4.3 PRODUCTS OFFERED
12.4.4 KEY DEVELOPMENTS.
12.4.5 SWOT ANALYSIS
12.4.6 KEY STRATEGIES
12.5 WUXI BIOLOGICS
12.5.1 COMPANY OVERVIEW
12.5.2 FINANCIAL OVERVIEW
12.5.3 PRODUCTS OFFERED
12.5.4 KEY DEVELOPMENTS
12.5.5 SWOT ANALYSIS
12.5.6 KEY STRATEGIES
12.6 RENTSCHLER BIOPHARMA SE
12.6.1 COMPANY OVERVIEW
12.6.2 FINANCIAL OVERVIEW
12.6.3 PRODUCTS/SERVICES OFFERED
12.6.4 KEY DEVELOPMENTS
12.6.5 KEY STRATEGIES
12.7 HORIZON DISCOVERY LTD
12.7.1 COMPANY OVERVIEW
12.7.2 FINANCIAL OVERVIEW
12.7.3 PRODUCTS OFFERED
12.7.4 KEY DEVELOPMENTS
12.7.5 KEY STRATEGIES
12.8 SARTORIUS AG
12.8.1 COMPANY OVERVIEW
12.8.2 FINANCIAL OVERVIEW
12.8.3 PRODUCTS/SERVICES OFFERED
12.8.4 KEY DEVELOPMENTS
12.8.5 SWOT ANALYSIS
12.8.6 KEY STRATEGIES
12.9 MERCK KGAA
12.9.1 COMPANY OVERVIEW
12.9.2 FINANCIAL OVERVIEW
12.9.3 PRODUCTS OFFERED
12.9.4 KEY DEVELOPMENTS
12.9.5 SWOT ANALYSIS
12.9.6 KEY STRATEGIES
12.10 FUJIFILM DIOSYNTH BIOTECHNOLOGIES INC.
12.10.1 COMPANY OVERVIEW
12.10.2 FINANCIAL OVERVIEW
12.10.3 PRODUCTS/SERVICES OFFERED
12.10.4 KEY DEVELOPMENT
12.10.5 KEY STRATEGIES

13 APPENDIX
13.1 REFERENCES
13.2 RELATED REPORTS